$9.97
0.080.81%
At Close: -
$9.97
00.00%
After Hours: 4:55 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
P10 (NYSE:PX) Stock, Analyst Ratings, Price Targets, Forecasts
P10 Inc has a consensus price target of $12 based on the ratings of 8 analysts. The high is $17 issued by JP Morgan on November 15, 2021. The low is $9 issued by Morgan Stanley on March 4, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, Barclays, and Morgan Stanley on March 4, 2024, respectively. With an average price target of $9.83 between Oppenheimer, Barclays, and Morgan Stanley, there's an implied -1.37% downside for P10 Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Barclays
Morgan Stanley
Keefe, Bruyette & Woods
JP Morgan
1calculated from analyst ratings
Analyst Ratings for P10
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/04/2024 | Buy Now | 10.33% | Oppenheimer | Chris Kotowski | $17 → $11 | Maintains | Outperform | Get Alert |
| 03/04/2024 | Buy Now | -4.71% | Barclays | Benjamin Budish | $14 → $9.5 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | -9.73% | Morgan Stanley | Michael Cyprys | $12 → $9 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/01/2024 | Buy Now | 0.3% | Keefe, Bruyette & Woods | Michael Brown | → $10 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/01/2024 | Buy Now | -4.71% | JP Morgan | Ken Worthington | $15.5 → $9.5 | Downgrade | Overweight → Neutral | Get Alert |
| 01/24/2024 | Buy Now | 20.36% | Morgan Stanley | Michael Cyprys | $13 → $12 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | 50.45% | Oppenheimer | Chris Kotowski | → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 11/10/2023 | Buy Now | 50.45% | Stephens & Co. | John Campbell | $16 → $15 | Maintains | Overweight | Get Alert |
| 10/18/2023 | Buy Now | 30.39% | Morgan Stanley | Michael Cyprys | $14 → $13 | Maintains | Overweight | Get Alert |
| 10/09/2023 | Buy Now | 50.45% | Oppenheimer | Chris Kotowski | $16 → $15 | Maintains | Outperform | Get Alert |
| 08/14/2023 | Buy Now | 40.42% | Morgan Stanley | Michael Cyprys | $13 → $14 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 60.48% | Stephens & Co. | John Campbell | $14 → $16 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 50.45% | Barclays | Benjamin Budish | $14 → $15 | Maintains | Overweight | Get Alert |
| 07/19/2023 | Buy Now | 30.39% | Morgan Stanley | Michael Cyprys | $13 → $13 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | Buy Now | 60.48% | Oppenheimer | Chris Kotowski | $17 → $16 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | 50.45% | Stephens & Co. | John Campbell | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 04/18/2023 | Buy Now | 45.44% | Keefe, Bruyette & Woods | Michael Brown | $15 → $14.5 | Maintains | Outperform | Get Alert |
| 04/13/2023 | Buy Now | 70.51% | Oppenheimer | Chris Kotowski | $15 → $17 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | 50.45% | Keefe, Bruyette & Woods | Michael Brown | $16 → $15 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | 50.45% | JP Morgan | Ken Worthington | $16 → $15 | Maintains | Overweight | Get Alert |
| 01/25/2023 | Buy Now | 70.51% | Oppenheimer | Chris Kotowski | $15 → $17 | Maintains | Outperform | Get Alert |
| 01/24/2023 | Buy Now | 40.42% | Morgan Stanley | Michael Cyprys | $15 → $14 | Maintains | Overweight | Get Alert |
| 12/19/2022 | Buy Now | 40.42% | Barclays | Benjamin Budish | $15 → $14 | Maintains | Overweight | Get Alert |
| 10/10/2022 | Buy Now | 40.42% | Barclays | Benjamin Budish | $15 → $14 | Maintains | Overweight | Get Alert |
| 08/31/2022 | Buy Now | 50.45% | Barclays | Benjamin Budish | → $15 | Initiates | → Overweight | Get Alert |
| 07/19/2022 | Buy Now | 50.45% | Morgan Stanley | Michael Cyprys | $16 → $15 | Maintains | Overweight | Get Alert |
| 04/20/2022 | Buy Now | 60.48% | Morgan Stanley | Michael Cyprys | $17 → $16 | Maintains | Overweight | Get Alert |
| 11/16/2021 | Buy Now | 70.51% | Stephens & Co. | John Campbell | — | Initiates | → Overweight | Get Alert |
| 11/15/2021 | Buy Now | 50.45% | UBS | — | — | Initiates | → Buy | Get Alert |
| 11/15/2021 | Buy Now | 80.54% | Morgan Stanley | Michael Cyprys | — | Initiates | → Overweight | Get Alert |
| 11/15/2021 | Buy Now | 70.51% | JP Morgan | Kenneth Worthington | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for P10 (PX) stock?
The latest price target for P10 (NYSE:PX) was reported by Oppenheimer on March 4, 2024. The analyst firm set a price target for $11.00 expecting PX to rise to within 12 months (a possible 10.33% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for P10 (PX)?
The latest analyst rating for P10 (NYSE:PX) was provided by Oppenheimer, and P10 maintained their outperform rating.
When was the last upgrade for P10 (PX)?
There is no last upgrade for P10
When was the last downgrade for P10 (PX)?
The last downgrade for P10 Inc happened on March 4, 2024 when Morgan Stanley changed their price target from $12 to $9 for P10 Inc.
When is the next analyst rating going to be posted or updated for P10 (PX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of P10, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for P10 was filed on March 4, 2024 so you should expect the next rating to be made available sometime around March 4, 2025.
Is the Analyst Rating P10 (PX) correct?
While ratings are subjective and will change, the latest P10 (PX) rating was a maintained with a price target of $17.00 to $11.00. The current price P10 (PX) is trading at is $9.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.